Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen

NCT03346200 is registered in ClinicalTrials.gov with Per Hall as lead sponsor.

NCT NCT03346200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03346200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen
Lead sponsor
Per Hall
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
December 31, 2019
Enrollment
1,440 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mammographic density reduction, risk reduction